hematological-systemImportantes avances en China en el tratamiento de la beta-talasemia grave mediante la edición genética CRISPR
CRISPR gene editing treated children with β0/β0 severe thalassemia have been free from blood transfusion dependence for 3 years, according to the research team, this is also the world's first reported successful clinical result of CRISPR gene editing for the treatment of children with severe thalassemia β0/β0 type.
Más información
